Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review)
- Authors:
- Mariana Díaz-Zaragoza
- Ricardo Hernández-Ávila
- Rubí Viedma‑Rodríguez
- Diego Arenas-Aranda
- Pedro Ostoa-Saloma
-
Affiliations: Departamento de Immunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510 México, DF, México, Unidad de Investigación Médica en Genética Humana, Centro Médico Nacional, Siglo XXI, Instituto Mexicano del Seguro Social, 06729 México, DF, México, Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510 México, DF, México - Published online on: June 30, 2015 https://doi.org/10.3892/or.2015.4095
- Pages: 1106-1114
-
Copyright: © Díaz-Zaragoza et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
 |
|
Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G and Hartwell L: The case for early detection. Nat Rev Cancer. 3:243–252. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Levenson VV: Biomarkers for early detection of breast cancer: What, when, and where? Biochim Biophys Acta. 1770:847–856. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Panieri E: Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol. 26:283–290. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Desmetz C, Mange A, Maudelonde T and Solassol J: Autoantibody signatures: Progress and perspectives for early cancer detection. J Cell Mol Med. 15:2013–2024. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
WHO: Early detection of cancer. http://www.who.int/cancer/detection/en/. | |
|
Lu H, Goodell V and Disis ML: Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 7:1388–1394. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 15:3363–3367. 1997.PubMed/NCBI | |
|
Carter P, Smith L and Ryan M: Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 11:659–687. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
WHO: Breast cancer: prevention and control. http://www.who.int/cancer/detection/breastcancer/en/. | |
|
Díaz-Zaragoza M, Hernández R and Ostoa-Saloma P: 2D immunoblots show differential response of mouse IgG and IgM antibodies to antigens of mammary carcinoma 4 T1 cells. Cancer Cell Int. 14:92014. View Article : Google Scholar | |
|
Klimovich VB: IgM and its receptors: Structural and functional aspects. Biochemistry (Mosc). 76:534–549. 2011. View Article : Google Scholar | |
|
Reynolds AE, Kuraoka M and Kelsoe G: Natural IgM is produced by CD5− plasma cells that occupy a distinct survival niche in bone marrow. J Immunol. 194:231–242. 2015. View Article : Google Scholar | |
|
Vollmers HP and Brändlein S: Natural antibodies and cancer. N Biotechnol. 25:294–298. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Brändlein S, Pohle T, Ruoff N, Wozniak E, Müller-Hermelink HK and Vollmers HP: Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63:7995–8005. 2003.PubMed/NCBI | |
|
Vollmers HP and Brändlein S: The 'early birds': Natural IgM antibodies and immune surveillance. Histol Histopathol. 20:927–937. 2005.PubMed/NCBI | |
|
Brändlein S, Eck M, Ströbel P, Wozniak E, Müller-Hermelink HK, Hensel F and Vollmers HP: PAM-1, a natural human IgM antibody as new tool for detection of breast and prostate precursors. Hum Antibodies. 13:97–104. 2004. | |
|
Vollmers HP and Brändlein S: Death by stress: Natural IgM-induced apoptosis. Methods Find Exp Clin Pharmacol. 27:185–191. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Manson JJ, Mauri C and Ehrenstein MR: Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 26:425–432. 2005. View Article : Google Scholar | |
|
Racine R, McLaughlin M, Jones DD, Wittmer ST, MacNamara KC, Woodland DL and Winslow GM: IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J Immunol. 186:1011–1021. 2011. View Article : Google Scholar : | |
|
Bendtzen K, Hansen MB, Ross C and Svenson M: High-avidity autoantibodies to cytokines. Immunol Today. 19:209–211. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Alberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Molecular Biology of the Cell. B Cells and Antibodies. 4th edition. Garland Science; New York, NY: 2002 | |
|
Lim HW, Hillsamer P, Banham AH and Kim CH: Cutting edge: Direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 175:4180–4183. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw PX, Hörkkö S, Chang MK, Curtiss LK, Palinski W, Silverman GJ and Witztum JL: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 105:1731–1740. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Austen WG Jr, Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD Jr, et al: Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA. 101:3886–3891. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ray SK, Putterman C and Diamond B: Pathogenic autoantibodies are routinely generated during the response to foreign antigen: A paradigm for autoimmune disease. Proc Natl Acad Sci USA. 93:2019–2024. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Casali P and Schettino EW: Structure and function of natural antibodies. Curr Top Microbiol Immunol. 210:167–179. 1996.PubMed/NCBI | |
|
Coutinho A, Kazatchkine MD and Avrameas S: Natural autoantibodies. Curr Opin Immunol. 7:812–818. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Panda S and Ding JL: Natural antibodies bridge innate and adaptive immunity. J Immunol. 194:13–20. 2015. View Article : Google Scholar | |
|
Lopes-Carvalho T and Kearney JF: Development and selection of marginal zone B cells. Immunol Rev. 197:192–205. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Madi A, Hecht I, Bransburg-Zabary S, Merbl Y, Pick A, Zucker-Toledano M, Quintana FJ, Tauber AI, Cohen IR and Ben-Jacob E: Organization of the autoantibody repertoire in healthy newborns and adults revealed by system level informatics of antigen microarray data. Proc Natl Acad Sci USA. 106:14484–14489. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Merbl Y, Zucker-Toledano M, Quintana FJ and Cohen IR: Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest. 117:712–718. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schettino EW, Chai SK, Kasaian MT, Schroeder HW Jr and Casali P: VHDJH gene sequences and antigen reactivity of monoclonal antibodies produced by human B-1 cells: Evidence for somatic selection. J Immunol. 158:2477–2489. 1997.PubMed/NCBI | |
|
Bohn J: Are natural antibodies involved in tumour defence? Immunol Lett. 69:317–320. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Boes M: Role of natural and immune IgM antibodies in immune responses. Mol Immunol. 37:1141–1149. 2000. View Article : Google Scholar | |
|
Vollmers HP and Brändlein S: Natural IgM antibodies: From parias to parvenus. Histol Histopathol. 21:1355–1366. 2006.PubMed/NCBI | |
|
Baumgarth N: The double life of a B-1 cell: Self-reactivity selects for protective effector functions. Nat Rev Immunol. 11:34–46. 2011. View Article : Google Scholar | |
|
Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC and Nagele RG: Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One. 8:e607262013. View Article : Google Scholar : PubMed/NCBI | |
|
Boes M, Schmidt T, Linkemann K, Beaudette BC, MarshakRothstein A and Chen J: Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA. 97:1184–1189. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hensel F, Brändlein S, Eck M, Schmidt K, Krenn V, Kloetzer A, Bachi A, Mann M, Müller-Hermelink HK and Vollmers HP: A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest. 81:1097–1108. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hensel F, Hermann R, Schubert C, Abé N, Schmidt K, Franke A, Shevchenko A, Mann M, Müller-Hermelink HK and Vollmers HP: Characterization of glycosylphosphatidylinositollinked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. 59:5299–5306. 1999.PubMed/NCBI | |
|
Rauschert N, Brändlein S, Holzinger E, Hensel F, MüllerHermelink H-K and Vollmers HP: A new tumor-specifc variant of GRP78 as target for antibody-based therapy. Lab Invest. 88:375–386. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kobata A and Amano J: Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol. 83:429–439. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Milner ECB, Anolik J, Cappione A and Sanz I: Human innate B cells: A link between host defense and autoimmunity? Springer Semin Immunopathol. 26:433–452. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Merino MC and Gruppi A: Origen y desarrollo de linfocitos B1, una población celular involucrada en defensa y autoinmunidad. Med (Buenos Aires). 165–172. 2006. | |
|
Notkins AL: Polyreactivity of antibody molecules. Trends Immunol. 25:174–179. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z-H, Tzioufas AG and Notkins AL: Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun. 29:219–228. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Manz RA, Hauser AE, Hiepe F and Radbruch A: Maintenance of serum antibody levels. Annu Rev Immunol. 23:367–386. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Baumgarth N, Chen J, Herman OC, Jager GC and Herzenberg LA: The role of B-1 and B-2 cells in immune protection from influenza virus infection. Curr Top Microbiol Immunol. 252:163–169. 2000.PubMed/NCBI | |
|
Carsetti R, Rosado MM and Wardmann H: Peripheral development of B cells in mouse and man. Immunol Rev. 197:179–191. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ogden CA, Kowalewski R, Peng Y, Montenegro V and Elkon KB: IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 38:259–264. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Quartier P, Potter PK, Ehrenstein MR, Walport MJ and Botto M: Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrowderived macrophages in vitro. Eur J Immunol. 35:252–260. 2005. View Article : Google Scholar | |
|
Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H and Zinkernagel RM: Control of early viral and bacterial distribution and disease by natural antibodies. Science. 286:2156–2159. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA and Chen J: B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med. 192:271–280. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Jayasekera JP, Moseman EA and Carroll MC: Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol. 81:3487–3494. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Khanna S, Goodyear CS, Park YB, Raz E, Thiel S, Grönwall C, Vas J, Boyle DL, Corr M, et al: Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol. 183:1346–1359. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers MC, Ryder LP, Koch C and Garred P: Mannosebinding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol. 33:2853–2863. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Boes M, Esau C, Fischer MB, Schmidt T, Carroll M and Chen J: Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol. 160:4776–4787. 1998.PubMed/NCBI | |
|
Rodríguez RC and Padilla CR: Compromiso del Sistema Inmune en Pacientes con Cáncer de Mama. Cancerología. 3:191–197. 2008.In spanish. | |
|
Zhang X: Regulatory functions of innate-like B cells. Cell Mol Immunol. 10:113–121. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H and Hersh EM: Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 169:1829–1836. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Llanes-Fernández L, Alvarez-Goyanes RI, Arango-Prado MC, Alcocer-González JM, Mojarrieta JC, Pérez XE, López MO, Odio SF, Camacho-Rodríguez R, Guerra-Yi ME, et al: Relationship between IL-10 and tumor markers in breast cancer patients. Breast. 15:482–489. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Burnet FM: Immunological surveillance in neoplasia. Transplant Rev. 7:3–25. 1971.PubMed/NCBI | |
|
Dunn GP, Old LJ and Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Karin M, Lawrence T and Nizet V: Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell. 124:823–835. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Vollmers HP and Brändlein S: Natural IgM antibodies: The orphaned molecules in immune surveillance. Adv Drug Deliv Rev. 58:755–765. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hoebe K, Janssen E and Beutler B: The interface between innate and adaptive immunity. Nat Immunol. 5:971–974. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Janeway CA Jr: Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 54:1–13. 1989.reprinted in J Immunol 191: 4475–4487, 2013. View Article : Google Scholar | |
|
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, et al: Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 26:281–293. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF and Kieber-Emmons T: Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine. 25:3022–3031. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, et al: Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 7:1490–1499. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tan HT, Low J, Lim SG and Chung MCM: Serum autoantibodies as biomarkers for early cancer detection. FEBs J. 276:6880–6904. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shishido SN, Varahan S, Yuan K, Li X and Fleming SD: Humoral innate immune response and disease. Clin Immunol. 144:142–158. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Priori ES, Seman G, Dmochowski L, Gallager HS and Anderson DE: Immunofluorescence studies on sera of patients with breast carcinoma. Cancer. 28:1462–1471. 1971. View Article : Google Scholar : PubMed/NCBI | |
|
Chan SP, Maca RD, Levine PH and Ting RC: Immunologic studies of human breast cancer. I. Serum reactivity against a lymphoid cell line (Belev) derived from a breast cancer patient as detected by complement-fixation test. J Natl Cancer Inst. 47:511–517. 1971.PubMed/NCBI | |
|
Roberts MM, Bathgate EM and Stevenson A: Serum immunoglobulin levels in patients with breast cancer. Cancer. 36:221–224. 1975. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts MM, Bass EM, Wallace IW and Stevenson A: Local immunoglobulin production in breast cancer. Br J Cancer. 27:269–275. 1973. View Article : Google Scholar : PubMed/NCBI | |
|
Fernández Madrid F: Autoantibodies in breast cancer sera: Candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 230:187–198. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Capurro M, Bover L, Portela P, Livingston P and Mordoh J: FC-215, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis (x) hapten. Cancer Immunol Immunother. 45:334–339. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Hensel F, Hermann R, Brändlein S, Krenn V, Schmausser B, Geis S, Müller-Hermelink HK and Vollmers HP: Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab Invest. 81:1553–1563. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Pohle T, Brändlein S, Ruoff N, Müller-Hermelink HK and Vollmers HP and Vollmers HP: Lipoptosis: Tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 64:3900–3906. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, shiau CW and Chen KF: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 15:R632013. View Article : Google Scholar : PubMed/NCBI | |
|
Brändlein S, Rauschert N, Rasche L, Dreykluft A, Hensel F, Conzelmann E, Müller-Hermelink HK and Vollmers HP: The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol Cancer Ther. 6:326–333. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Verring A, Clouth A, Ziolkowski P and Oremek GM: Clinical usefulness of cancer markers in primary breast cancer. ISRN Pathol. 2011:8176182011. View Article : Google Scholar | |
|
Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K and Livingston PO: Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol. 174:5706–5712. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY and Herlyn D: Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother. 57:1079–1089. 2008. View Article : Google Scholar | |
|
Pashov A, Monzavi-Karbassi B and Kieber-Emmons T: Immune surveillance and immunotherapy: Lessons from carbohydrate mimotopes. Vaccine. 27:3405–3415. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hadden JW: The immunology and immunotherapy of breast cancer: An update. Int J Immunopharmacol. 21:79–101. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, van Kamp GJ, Paul MA, Van Diest PJ, Meijer S and Hilgers J: Survival in early breast cancer patients is favorably infuenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin oncol. 18:574–583. 2000.PubMed/NCBI | |
|
Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L and Livingston PO: Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 6:1693–1701. 2000.PubMed/NCBI | |
|
Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G and Livingston P: Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer. 79:1806–1812. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Conry RM, Allen KO, Lee S, Moore SE, Shaw DR and LoBuglio AF: Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res. 6:34–41. 2000.PubMed/NCBI | |
|
Albanopoulos K, Armakolas A, Konstadoulakis MM, leandros E, Tsiompanou E, Katsaragakis S, Alexiou D and Androulakis G: Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol. 95:1056–1061. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Dube VE, Haid M, Chmiel JS and Anderson B: Serum cold agglutinin and IgM levels in breast carcinoma. Breast Cancer Res Treat. 4:105–108. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Botti C, Martinetti A, Nerini-Molteni S and Ferrari L: Antimalignin antibody evaluation: A possible challenge for cancer management. Int J Biol Markers. 12:141–147. 1997. | |
|
Thornthwaite JT: Anti-malignin antibody in serum and other tumor marker determinations in breast cancer. Cancerlett. 148:39–48. 2000. | |
|
Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, et al: Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res. 13:2977–2985. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang TC, Li H, Huang GN and Wang SY: Detection of IgM and IgG complexes provides new insight into immune regulation of patients with malignancies: A randomized controlled trial. Int Immunopharmacol. 7:1433–1441. 2007. View Article : Google Scholar : PubMed/NCBI |
